Application of MMP7, CTSE or LAMC2 proteins in preparation of intrahepatic cholangiocarcinoma diagnostic reagent

A technology for inner bile duct and cell carcinoma, which is applied in the field of medical bioengineering and can solve the problems of unsatisfactory sensitivity and specificity

Active Publication Date: 2020-12-25
杭州道合天孚生物科技有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although carbohydrate antigen 125, carbohydrate antigen 19-9, and carcinoembryonic antigen are clinically used as reference markers for the diagnosis of cholangiocarcinoma, they all have high expression values ​​in ductal cancers, and their sensitivity and The specificity is not ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of MMP7, CTSE or LAMC2 proteins in preparation of intrahepatic cholangiocarcinoma diagnostic reagent
  • Application of MMP7, CTSE or LAMC2 proteins in preparation of intrahepatic cholangiocarcinoma diagnostic reagent
  • Application of MMP7, CTSE or LAMC2 proteins in preparation of intrahepatic cholangiocarcinoma diagnostic reagent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1: The detection of plasma MMP7, CTSE, and LAMC2 helps to improve the clinical diagnostic ability of intrahepatic cholangiocarcinoma.

[0050] A total of 98 volunteers were selected in a hospital, including 39 patients with intrahepatic cholangiocarcinoma, 22 healthy people, 20 patients with benign biliary tract disease and 17 patients with hepatocellular carcinoma. Extract biological samples from volunteers, record characteristic parameters, and use kits for specific detection. The characteristic parameters of the test group are shown in Table 1.

[0051] Table 1. Clinical characteristics of 39 patients with intrahepatic cholangiocarcinoma, 17 patients with hepatocellular carcinoma, and 20 patients with benign biliary disease

[0052] a: Fisher's exact test; b: chi-square test; c: variance test

[0053]

[0054]

[0055]

[0056] In this experiment, the commercially available antibody sandwich method was used to detect the three proteins. Standard pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention relates to the technical field of medical bioengineering, and aims to provide an application of MMP7, CTSE or LAMC2 proteins in preparation of an intrahepatic cholangiocarcinoma diagnosis reagent. The application is used for preparing a reagent capable of identifying and diagnosing intrahepatic cholangiocarcinoma and distinguishing primary hepatocellular carcinoma by using at least one of the MMP7, the CTSE or the LAMC2 proteins, which means the identification and the distinguishing of the hepatocellular carcinoma and the intrahepatic cholangiocarcinoma are achieved by using thethree proteins independently or in a combined manner. According to the application of the MMP7, the CTSE or the LAMC2 proteins in preparation of the intrahepatic cholangiocarcinoma diagnosis reagent,the reagent or a kit product is prepared from the three proteins, the expression level of the proteins in blood is detected by an immunological related method and is used as a basis for diagnosing anintrahepatic cholangiocarcinoma marker. The application of the MMP7, the CTSE or the LAMC2 proteins in preparation of the intrahepatic cholangiocarcinoma diagnosis reagent can accurately and specifically judge the possibility of the intrahepatic cholangiocarcinoma, benign biliary diseases, the hepatocellular carcinoma and health status of a subject, and provides a basis of the next diagnosis and treatment scheme for doctors.

Description

[0001] This application is required to be submitted to the State Intellectual Property Office of China on October 21, 2019. The patent application number is 201911002168.5, and the title of the invention is "Application of MMP7, CTSE or LAMC2 protein in the preparation of diagnostic reagents for intrahepatic cholangiocarcinoma". priority. technical field [0002] The invention belongs to the technical field of medical bioengineering, and particularly relates to the application of MMP7, CTSE or LAMC2 protein in the preparation of diagnostic reagents for intrahepatic cholangiocarcinoma. Background technique [0003] Intrahepatic cholangiocarcinoma accounts for 10%-15% of primary liver tumors and is the second most common primary liver cancer. Intrahepatic cholangiocarcinoma has no obvious clinical symptoms in the early stage, and most patients have developed to an advanced stage when they are diagnosed, and have lost the opportunity for surgery. Intrahepatic cholangiocarcinom...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N33/574G01N33/573
CPCG01N33/573G01N33/57407G01N33/57484G01N33/68G01N2333/78G01N2333/96472G01N2333/96494
Inventor 姬峻芳张剑娟
Owner 杭州道合天孚生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap